IONAMIN
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASEPriority Review
Approved
May 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IONAMIN is an oral extended-release capsule small molecule approved in 1959 by UCB Pharma. The generic name and mechanism of action are not currently available in this dataset. The product treats an unknown indication but represents a legacy NDA with approaching loss of exclusivity.
LOE Approaching
As LOE approaches, the brand team is likely in defensive mode with limited growth opportunities; headcount and investment typically decline post-LOE.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and LOE-approaching lifecycle make IONAMIN a poor career growth opportunity. Professionals on this brand should prepare for transition as the product moves into generic competition and team reductions.
Brand ManagerField Sales Representative
Worked on IONAMIN at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.